Stilund Morten, Gjelstrup Mikkel Carstensen, Christensen Tove, Møller Holger Jon, Petersen Thor
Department of Neurology Aarhus University Hospital Nørrebrogade 44 DK-8000 Aarhus C Denmark; Department of Biomedicine Aarhus University Bartholin Building, Wilhelm Meyers Allé 4 DK-8000 Aarhus C Denmark.
Department of Biomedicine Aarhus University Bartholin Building, Wilhelm Meyers Allé 4 DK-8000 Aarhus C Denmark.
Brain Behav. 2016 Jul 11;6(9):e00509. doi: 10.1002/brb3.509. eCollection 2016 Sep.
This study aimed to examine the levels of the macrophage marker sCD163 and other biomarkers at the time of diagnosis of patients with either clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS), and assess relation to clinical indicators of prognosis, disease activity (DA), and changes in the levels of these biomarkers at follow-up.
The clinical status and MRI were reevaluated in 56 patients more than 1 year after diagnosis with a median follow-up time of 2 years. Levels of biomarkers in serum and cerebrospinal fluid (CSF) samples were evaluated by enzyme-linked immunosorbent assays.
There was no significant difference in time to DA between patients with CIS and RRMS. A high sCD163 ratio (>0.07) was significantly ( = 0.04) associated with time to DA in the untreated patient group. In 21 patients reevaluated with serum and CSF samples, the sCD163 ratio levels decreased from 0.068 to 0.054 ( = 0.026) in the CIS/RRMS-treated group. The CSF CXCL13, CXCL13 ratio, CSF neurofilament light polypeptide and osteopontin levels also decreased significantly in the CIS/RRMS-treated group.
The levels of all biomarkers changed concurrently with MS treatment. The sCD163 ratio was identified as a potential novel marker for time to DA.
本研究旨在检测临床孤立综合征（CIS）或复发缓解型多发性硬化症（RRMS）患者诊断时巨噬细胞标志物可溶性 CD163（sCD163）及其他生物标志物的水平，并评估其与预后临床指标、疾病活动度（DA）的关系以及随访期间这些生物标志物水平的变化。
对 56 例诊断超过 1 年的患者重新评估临床状况和磁共振成像（MRI），中位随访时间为 2 年。采用酶联免疫吸附测定法评估血清和脑脊液（CSF）样本中的生物标志物水平。
CIS 患者和 RRMS 患者达到疾病活动度的时间无显著差异。在未治疗患者组中，高 sCD163 比值（>0.07）与达到疾病活动度的时间显著相关（P = 0.04）。在 21 例重新评估血清和脑脊液样本的患者中，CIS/RRMS 治疗组的 sCD163 比值水平从 0.068 降至 0.054（P = 0.026）。CIS/RRMS 治疗组的脑脊液 CXCL13、CXCL13 比值、脑脊液神经丝轻链多肽和骨桥蛋白水平也显著降低。
所有生物标志物的水平均随多发性硬化症治疗而同步变化。sCD163 比值被确定为达到疾病活动度时间的潜在新标志物。
